All patients with bilateral, trilateral or familial retinoblastoma have to be considered as carriers of a heritable tumor predisposition syndrome, even if no molecular genetic analysis was performed or in the absence of detection of the oncogenic RB1 variant in blood DNA. Here, RB1 is linked to BAP1-related tumor predisposition syndrome.